logo
welcome
Reuters

Reuters

Pfizer withdraws sickle cell disease treatment from all markets

Reuters
Summary
Nutrition label

80% Informative

Pfizer withdraws sickle cell disease therapy Oxbryta in all markets where it is approved.

The company said it does not anticipate that the withdrawal will impact its full-year 2024 financial outlook.

Pfizer acquired the therapy as part of its $5.4 billion buyout of Global Blood Therapeutics in 2022 .

VR Score

90

Informative language

96

Neutral language

62

Article tone

semi-formal

Language

English

Language complexity

57

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links